BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kraemer B, Abele H, Hahn M, Rajab T, Kraemer E, Wallweiner D, Becker S. A successful pregnancy in a patient with Takayasu’s arteritis. Hypertens Pregnancy. 2008;27:247-252. [PMID: 18696353 DOI: 10.1080/10641950801955741] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Shafi NA, Malik A, Silverman DI. Management of Takayasu Arteritis During Pregnancy. The Journal of Clinical Hypertension 2009;11:383-5. [DOI: 10.1111/j.1751-7176.2009.00135.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
2 Dagli AI, Lee PJ, Correia CE, Rodriguez C, Bhattacharya K, Steinkrauss L, Stanley CA, Weinstein DA. Pregnancy in glycogen storage disease type Ib: gestational care and report of first successful deliveries. J Inherit Metab Dis 2010;33 Suppl 3:S151-7. [PMID: 20386986 DOI: 10.1007/s10545-010-9054-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
3 Dalkilic E, Coskun BN, Yağız B, Pehlivan Y. A successful pregnancy in a patient with Takayasu's arteritis under tocilizumab treatment: A longitudinal case study. Int J Rheum Dis 2019;22:1941-4. [DOI: 10.1111/1756-185x.13687] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Vinet E, Pineau C, Gordon C, Clarke AE, Bernatsky S. Biologic therapy and pregnancy outcomes in women with rheumatic diseases. Arthritis Rheum 2009;61:587-92. [PMID: 19404999 DOI: 10.1002/art.24462] [Cited by in Crossref: 59] [Cited by in F6Publishing: 31] [Article Influence: 4.9] [Reference Citation Analysis]
5 Bérard A, Zhao J, Shui I, Colilla S. Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes. Ann Rheum Dis 2018;77:500-9. [DOI: 10.1136/annrheumdis-2017-212078] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 6.5] [Reference Citation Analysis]
6 Mena-vazquez N. Safety of biologic therapies during pregnancy in women with rheumatic disease. WJR 2015;5:82. [DOI: 10.5499/wjr.v5.i2.82] [Cited by in CrossRef: 1] [Article Influence: 0.2] [Reference Citation Analysis]
7 Marchioni RM, Lichtenstein GR. Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review. World J Gastroenterol. 2013;19:2591-2602. [PMID: 23674866 DOI: 10.3748/wjg.v19.i17.2591] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 52] [Article Influence: 10.0] [Reference Citation Analysis]
8 Raja H, Matteson EL, Michet CJ, Smith JR, Pulido JS. Safety of Tumor Necrosis Factor Inhibitors during Pregnancy and Breastfeeding. Transl Vis Sci Technol 2012;1:6. [PMID: 24049706 DOI: 10.1167/tvst.1.2.6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
9 Gatto M, Iaccarino L, Canova M, Zen M, Nalotto L, Ramonda R, Punzi L, Doria A. Pregnancy and vasculitis: A systematic review of the literature. Autoimmunity Reviews 2012;11:A447-59. [DOI: 10.1016/j.autrev.2011.11.019] [Cited by in Crossref: 49] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
10 de Souza AW, da Silva MD, Machado LS, Oliveira AC, Pinheiro FA, Sato EI. Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study. Scand J Rheumatol 2012;41:227-30. [PMID: 22400913 DOI: 10.3109/03009742.2011.633553] [Cited by in Crossref: 52] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
11 Papadopoulou A, Kappos L, Sprenger T. Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis. Expert Opinion on Drug Safety 2015;14:749-59. [DOI: 10.1517/14740338.2015.1014795] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
12 Pfaller B, Pupco A, Leibson T, Aletaha D, Ito S. A critical review of the reproductive safety of Leflunomide. Clin Rheumatol 2020;39:607-12. [DOI: 10.1007/s10067-019-04819-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
13 Clowse ME. The use of anti-TNFα medications for rheumatologic disease in pregnancy. Int J Womens Health 2010;2:199-209. [PMID: 21072312 DOI: 10.2147/ijwh.s6029] [Cited by in Crossref: 25] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
14 Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler DA, Finlay AY, Griffiths CE, Jackson K, McHugh NJ. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009;161:987-1019. [PMID: 19857207 DOI: 10.1111/j.1365-2133.2009.09505.x] [Cited by in Crossref: 308] [Cited by in F6Publishing: 226] [Article Influence: 28.0] [Reference Citation Analysis]
15 Cassina M, Johnson DL, Robinson LK, Braddock SR, Xu R, Jimenez JL, Mirrasoul N, Salas E, Luo YJ, Jones KL, Chambers CD; for the Organization of Teratology Information Specialists Collaborative Research Group. Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis & Rheumatism 2012;64:2085-94. [DOI: 10.1002/art.34419] [Cited by in Crossref: 88] [Cited by in F6Publishing: 64] [Article Influence: 9.8] [Reference Citation Analysis]
16 Garip Y. Use of biologic agents for rheumatic diseases in pregnancy. WJR 2015;5:50. [DOI: 10.5499/wjr.v5.i2.50] [Reference Citation Analysis]